Matches in Wikidata for { <http://www.wikidata.org/entity/Q104680092> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q104680092 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 23ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104680092 description "article scientifique publié en 2020" @default.
- Q104680092 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104680092 description "scientific article published on 23 December 2020" @default.
- Q104680092 description "wetenschappelijk artikel" @default.
- Q104680092 description "наукова стаття, опублікована 23 грудня 2020" @default.
- Q104680092 name "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 name "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 name "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 type Item @default.
- Q104680092 label "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 label "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 label "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 prefLabel "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 prefLabel "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 prefLabel "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 P1433 Q104680092-A4AEC490-AA8C-43B4-B981-DD71DB0FC1FB @default.
- Q104680092 P1476 Q104680092-33299CB4-4A87-409A-9737-939EB8B8C7E2 @default.
- Q104680092 P2093 Q104680092-25A917A1-29BA-4FCD-BB84-EA1170F1F248 @default.
- Q104680092 P2093 Q104680092-65DF8E32-66D4-4080-85C5-ADF3BD1A5AB5 @default.
- Q104680092 P2093 Q104680092-BD950D86-2921-45F8-9C72-6C1FF48DECD3 @default.
- Q104680092 P2093 Q104680092-D35DD474-311B-4574-846F-457D6163BE3F @default.
- Q104680092 P275 Q104680092-f8d15696-0e0c-45ca-819e-28d999f261c5 @default.
- Q104680092 P304 Q104680092-0A588DDB-8D73-43F2-BCA0-C79A33851921 @default.
- Q104680092 P31 Q104680092-B6E1C1B6-B7FE-473D-97EC-76E4DC5F8351 @default.
- Q104680092 P356 Q104680092-604C2484-F906-48AA-B2FE-F9E53408C013 @default.
- Q104680092 P478 Q104680092-2C9C20FC-1AA3-449F-8B7C-2B61DD831A1D @default.
- Q104680092 P50 Q104680092-64FA5DA4-81AE-43E0-A171-A2EA5FA3B1C9 @default.
- Q104680092 P50 Q104680092-98C08166-E279-4AB6-99E0-5D474C4AA0E0 @default.
- Q104680092 P50 Q104680092-AF20802A-B075-4B6D-B7F6-7531BE821AC5 @default.
- Q104680092 P577 Q104680092-576B2AC0-A88B-41DC-B558-4E9146ACFF82 @default.
- Q104680092 P6216 Q104680092-f52c2a3f-8c44-43bf-8b25-ca0b910294b0 @default.
- Q104680092 P698 Q104680092-6D1A43F2-6817-4539-884D-34C98AE29954 @default.
- Q104680092 P921 Q104680092-BEF3E565-A251-45F8-A167-651EA97C90F2 @default.
- Q104680092 P932 Q104680092-D2C5BAE2-A971-40CC-BD43-9AC4B7945D63 @default.
- Q104680092 P356 NDT.S286654 @default.
- Q104680092 P698 33380797 @default.
- Q104680092 P1433 Q15716332 @default.
- Q104680092 P1476 "Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia" @default.
- Q104680092 P2093 "Annette Wooller" @default.
- Q104680092 P2093 "Maju Mathews" @default.
- Q104680092 P2093 "Martin Lambert" @default.
- Q104680092 P2093 "Paul Bergmans" @default.
- Q104680092 P275 Q18810331 @default.
- Q104680092 P304 "3197-3208" @default.
- Q104680092 P31 Q13442814 @default.
- Q104680092 P356 "10.2147/NDT.S286654" @default.
- Q104680092 P478 "16" @default.
- Q104680092 P50 Q80665361 @default.
- Q104680092 P50 Q90409828 @default.
- Q104680092 P50 Q90409832 @default.
- Q104680092 P577 "2020-12-23T00:00:00Z" @default.
- Q104680092 P6216 Q50423863 @default.
- Q104680092 P698 "33380797" @default.
- Q104680092 P921 Q41112 @default.
- Q104680092 P932 "7767727" @default.